Roger Whiting, Ph.D.
Dr. Roger Whiting is a co-founder, president and chief scientific officer of Roxro Pharma Inc., a privately owned, virtually organized specialty pharmaceutical company focused on developing innovative treatments for pain. A veteran of the pharmaceutical industry, Dr. Whiting has held a range of scientific and management positions over the past 30 years.
Prior to co-founding Roxro, Dr. Whiting worked for many years at Syntex Research in Scotland and Palo Alto. As Senior Vice President of Syntex Discovery Research, North America, he led research and early development programs, and defined the company’s fledgling program in pain. After Roche purchased Syntex, Dr. Whiting was instrumental in creating Roche Bioscience, which represented a novel approach to research and development in the pharmaceutical industry. Dr. Whiting was a Senior Vice President and Head of the Neurology Business Unit at Roche Bioscience, where he managed comprehensive programs in pain and urology through to clinical proof-of-concept. He started his career at Beecham Research Laboratories in England.
Dr. Whiting has authored more than 100 papers, and is an inventor on 18 patents. He also serves on the steering committees of several publications and as a journal referee.
Dr. Whiting earned his Ph.D. from Aston University.
